思路迪-埃提斯：抗肿瘤个体化精准药物研发平台

A graduate of the Shanghai Institutes for Biological Sciences (SIBS) of the Chinese Academy of Sciences (CAS), Dr. Lei Xiong made the decision to quit his post-doctoral studies in University of Zurich and returned to China in 2011. With other five individuals holding advanced academic degrees, Dr. Xiong launched 3D-HTS, intending to reform the traditional method of antitumor medicine R&D using high throughput screening technology. This case first describes the “dual-low” phenomena (low effectiveness ratio and low approval ratio) that had frustrated antitumor pharmaceutical companies throughout the world. By reviewing the start up of Dr. Xiong’s business, students will consider how to foresee industry trends and accumulate resources. In the following two years, how did Xiong make strategic adjustments to take advantage of big data and the rising market? To minimize the risks of innovation in an emerging high-tech industry, 3D-HTS now faces questions of future talent management, market expansion, capital development and policy guidance. This case is suited for discussion of business models, investment, strategy, entrepreneurship and innovation.